Lucid Diagnostics Inc. · NASDAQ:LUCD

Lucid Diagnostics — Q2 2026 Earnings Presentation

12 slides from Lucid Diagnostics's earnings presentation, Aug 13, 2026

1. Slide 1: Q2 2026 Business Update

   Nasdaq: LUCD Q2 2026 Business Update August 13, 2026 Lishan Aklog MD Dennis McGrath Chairman & CEO CFO

2. Slide 2: Disclaimer

   Disclaimer ▪ This presentation may contain certain forward-looking statements related to or Lucid Diagnostics Inc. (the “Company”) that involve risks and uncertainties. ▪ Actual results and events may differ significantly from results and events discussed in forward- looking statements. ▪ Factors th

3. Slide 3: Lishan Aklog, M.D. Chairman & CEO

   Lishan Aklog, M.D. Chairman & CEO

4. Slide 4: Highlights

   Highlights ▪ Key Highlights – 2Q26 EsoGuard test volume: 2,770 – 2Q26 Revenue: $1.5M – Secured first LBM commercial coverage policy from Concert – Concert policy already adopted by multiple client health plans 4

5. Slide 5: Business Update

   ms (b) Lucid diagnostics Business Update

6. Slide 6: Market Access & Commercialization

   Market Access & Commercialization Medicare Veterans Affairs Commercial Coverage HEOR Health Economics & Outcomes Health Systems Research 6

7. Slide 7: Q2 2026 Financial Update

   Q2 2026 Financial Update Dennis McGrath, CFO

8. Slide 8: Balance Sheet

   Balance Sheet ($ in thousands) 2Q26 1Q26 Change Assets Cash $33,404 $27,876 $5,528 Fixed Assets $810 $907 $(97) All other Assets $4,732 $5,297 $(565) Liabilities Accounts Payable $667 $1,077 $(410) Senior Secured Convertible Notes $23,500 $25,200 $(1,700) Other Current Liabilities $3,349 $3,108 $241

9. Slide 9: P&L ($ in thousands) 2Q26

   P&L ($ in thousands) 2Q26 2Q25 Change 2Q26 - YTD 2Q25 - YTD Change Revenue $1,474 $1,163 $311 $2,730 $1,991 $739 Operating Expenses $14,275 $12,547 $1,728 $27,644 $25,862 $1,782 Net Loss $(11,687) $(4,439) $(7,248) $(25,596) $(31,347) $5,751 1 2 EBITDA $(11,536) $(4,321) $(7,215) $(25,287) $(31,066)

10. Slide 10: Non-GAAP Operating Expense

    Non-GAAP Operating Expense 8,000 16,000 14,139 7,000 14,000 11,511 12,328 6,000 11,109 12,000 11,709 5,000 10,000 4,000 8,000 3,000 6,000 2,000 4,000 1,000 2,000 0 0 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Cost of Revenue Sales and Marketing General & Admin R&D Total To supplement our unaudited fina

11. Slide 11: Q&A

    Q&A

12. Slide 12: Closing Remarks

    ms (b) Lucid diagnostics Closing Remarks

Lucid Diagnostics — Q2 2026 Earnings Presentation on 6ix